Search

everythinglearnresearchcommunity

for

Search:↓

This review analyzes recent scientific evidence on the neuroendocrine and metabolic impacts of chronic use of 5-alpha reductase inhibitors, focusing on Post-Finasteride Syndrome (PFS). The study, based on eight high-impact studies from 2021 to 2026, highlights PFS as a multisystemic condition linked to the use of 5-ARIs, with reports of refractory sexual dysfunction and mood disorders in young patients. The inhibition of enzymes in the central nervous system suppresses the synthesis of active metabolites like allopregnanolone, leading to GABAergic dysregulation and excitotoxicity. Metabolically, the suppression of dihydrotestosterone is associated with insulin resistance, non-alcoholic fatty liver disease, Type 2 Diabetes Mellitus, and changes in gut microbiota. Genetic polymorphisms in the SRD5A2 gene and epigenetic changes, such as DNA methylation of the androgen receptor, contribute to the chronicity of symptoms. The findings suggest that PFS extends beyond transient side effects, emphasizing the need for personalized medicine models and strengthened informed consent protocols to mitigate persistent biopsychosocial risks.

The study investigates the catalytic mechanism of steroid 5α-reductase type 2 (SRD5A2), focusing on the dynamic interactions among residues that affect enzyme kinetics. Using QM/MM simulations, it was found that residues Tyr33 and L224 compress the donor, altering free energy barriers and supporting the preorganization theory. Additionally, six other residues (Trp53, Arg94, Cys119, Glu197, Phe223, and Arg227) form a network that stabilizes transition states through electrostatic and structural interactions. The L224P mutant analysis shows that losing L224 compression increases energy barriers by 3.3-3.4 kcal/mol, highlighting the importance of dynamic and electrostatic coordination for efficient catalysis.

This meta-analysis examined the risk of depression associated with 5-alpha reductase inhibitors (5-ARIs) across 5 longitudinal studies involving 2,517,859 patients. The findings indicate a 31% increased risk of depression with 5-ARI use, though this risk varies significantly depending on the control group used. Studies with non-drug controls reported a higher risk, while those with alpha-blocker comparators showed a decreased risk. The choice of comparator group was a major source of heterogeneity in the results. Overall, the risk of depression with 5-ARI use is likely minimal, with observational data suggesting a slight reduction in risk and randomized data indicating a potential slight increase. Previous reports of a much higher risk may have resulted from inappropriate control group selection.